KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Capital Expenditures (2016 - 2025)

Merck (MRK) has disclosed Capital Expenditures for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 10.25% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 billion, a 21.95% increase, with the full-year FY2025 number at $4.1 billion, up 21.95% from a year prior.
  • Capital Expenditures was $1.0 billion for Q4 2025 at Merck, up from $987.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.3 billion in Q1 2025 to a low of $764.0 million in Q2 2025.
  • A 5-year average of $1.0 billion and a median of $988.0 million in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 288.08% in 2021, then decreased 19.89% in 2023.
  • Merck's Capital Expenditures stood at $1.2 billion in 2021, then decreased by 4.88% to $1.1 billion in 2022, then fell by 13.93% to $989.0 million in 2023, then decreased by 5.26% to $937.0 million in 2024, then increased by 10.25% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Capital Expenditures are $1.0 billion (Q4 2025), $987.0 million (Q3 2025), and $764.0 million (Q2 2025).